Literature DB >> 3558723

Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea.

J Schlechte, G el-Khoury, M Kathol, L Walkner.   

Abstract

To determine whether women with PRL-secreting pituitary tumors have similar decreases in cortical and trabecular bone and to determine whether bone loss associated with hyperprolactinemia is reversible, we measured forearm and vertebral bone mineral in normal women and in amenorrheic women with treated and untreated hyperprolactinemia. The mean spinal bone mineral content in hyperprolactinemic women [130 +/- 23 (+/- SD) mg/mL] was 25% lower than that in normal women (167 +/- 28 mg/mL), while the mean forearm bone mineral content (0.71 +/- 0.04 g/cm2) was similar to that in normal women (0.73 +/- 0.05 g/cm2). Women with normal serum PRL levels and regular menses after transsphenoidal surgery had slightly higher mean spinal bone mineral content (149 +/- 28 mg/mL) than women who remained amenorrheic after surgery (129 +/- 19 mg/mL), but the mean value in the cured women remained significantly lower than that in normal women. In contrast, women who had undergone successful transsphenoidal pituitary surgery had mean forearm bone mineral comparable to that in normal women. There was no correlation between vertebral and radial bone mineral in hyperprolactinemic women and no correlation between bone mineral and serum PRL, serum estradiol, or duration of amenorrhea when age was taken into account. These findings suggest that hyperprolactinemia and/or decreased gonadal function in women with PRL-secreting pituitary tumors are associated with more prominent effects on trabecular bone in the spine than on cortical bone in the wrist. In addition, the abnormal spinal bone mineral content after successful treatment suggest that normalization of estradiol and PRL secretion is not sufficient to restore bone mineral content to normal, although it may be stabilized.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3558723     DOI: 10.1210/jcem-64-5-1021

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

Authors:  Chadi A Calarge; Bridget Zimmerman; Diqiong Xie; Samuel Kuperman; Janet A Schlechte
Journal:  J Clin Psychiatry       Date:  2010-03       Impact factor: 4.384

2.  Prevalence of osteopenia in men with prolactinoma.

Authors:  E C O Naliato; M L F Farias; G R Braucks; F S R Costa; D Zylberberg; A H D Violante
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

3.  Post-traumatic hormonal disturbances: prolactin as a link between head injury and enhanced osteogenesis.

Authors:  R Wildburger; N Zarkovic; G Tonkovic; T Skoric; S Frech; M Hartleb; I Loncaric; K Zarkovic
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

Review 4.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

5.  Reversal of severe osteopenia in a patient with hyperprolactinemia treated with bromocriptine.

Authors:  J S Lindberg; F O Kolb; R A Blau; M R Powell
Journal:  West J Med       Date:  1988-09

Review 6.  Do nothing but observe microprolactinomas: when and how to replace sex hormones?

Authors:  Vivien Bonert
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

Review 7.  The evaluation and management of subclinical pituitary disease.

Authors:  S G Soule; H S Jacobs
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

Review 8.  Treatment of hyperprolactinemia in post-menopausal women: pros.

Authors:  D Iacovazzo; L De Marinis
Journal:  Endocrine       Date:  2014-08-12       Impact factor: 3.633

9.  Bone mineral density in hyperandrogenic amenorrhoea.

Authors:  J Prezelj; A Kocijancic
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

Review 10.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.